GlassScriptPhysician profile
Tudor Sturzoiu
NPI 1790341964
$3,770.77
in general payments reported to CMS, 2019-2025
20 companies · $2,982 in 2025
The $2,982 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $179 · 2023: $41.40 · 2024: $568 · 2025: $2,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $2,000 · Food and Beverage: $1,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $2,000.00 |
| Food and Beverage | $1,591.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,012.99 | 2022-2025 | |
| Boston Scientific Corporation | $510.71 | 2024-2025 | Avvigo Guidance System |
| Shockwave Medical, INC | $157.47 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biotronik INC. | $146.29 | 2022 | |
| Teleflex LLC | $128.06 | 2025 | Turnpike |
| Angiodynamics, INC. | $127.80 | 2025 | Alphavac |
| Philips North America LLC | $127.49 | 2025 | Labosys |
| Heartflow, INC. | $110.93 | 2024 | |
| Cagent Vascular INC | $102.46 | 2025 | Serrantor |
| Bracco Diagnostics INC. | $52.37 | 2025 | |
| Pfizer INC. | $48.81 | 2023-2024 | |
| Abbott Laboratories | $41.11 | 2024 | Quadra Assura, Assurity |
| Janssen Pharmaceuticals, INC | $39.49 | 2024 | Xarelto |
| Novo Nordisk INC | $35.00 | 2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $28.07 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $26.67 | 2025 | |
| Merck Sharp & Dohme LLC | $22.41 | 2023 | Verquvo |
| Edwards Lifesciences Corporation | $19.69 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.49 | 2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $16.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tudor Sturzoiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.